SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549



                                    FORM 8-K


                Current Report Pursuant to Section 13 or 15(d) of
                           The Securities Act of 1934



Date of Report (Date of earliest event reported):             September 6, 2000


                         MEDITECH PHARMACEUTICALS, INC.
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)


      NEVADA                         0-12561                    95-3819300
  (State or other                  (Commission               (I.R.S. Employer
   jurisdiction                   File Number)              Identification No.)
 of incorporation)

                             10105 E. Via Linda, #103
                                     PMB 382
                                Phoenix, Arizona                        85258
                       --------------------------------------          --------
                      (Address of principal executive offices)        (Zip Code)


Registrant's telephone number, including area code:  (480) 614-2874




<PAGE>



ITEM 5.  OTHER EVENTS.

     On September 6, 2000, the Company's Board of Directors approved the
engagement of Singer Lewak Greenbaum & Goldstein LLP, as the Company's
independent certified public accountants, to audit the Company's financial
statements for the fiscal year ending May 31, 2001. Singer Lewak Greenbaum &
Goldstein, LLP, was also engaged to audit the Company's financial statements for
the fiscal years ended May 31, 2000, and each of the two years in the period
then ended, for inclusion in a Form SB-2 registration statement which will be
filed by the Company. The engagement of Singer Lewak Greenbaum & Goldstein LLP,
follows the replacement of Roy A. Cohen, C.P.A., who had been engaged to audit
the Company's financial statements for the fiscal years ended May 31, 1985
through 2000. The audit reports provided by Roy A. Cohen, C.P.A. for the prior
two fiscal years did not contain an adverse opinion or disclaimer of opinion;
however, the audit reports for such periods did contain a going concern
qualification.

     Management of the Company knows of no past or present disagreements between
the Company and Roy A. Cohen, C.P.A., on any matter of accounting principles or
practices, financial statement disclosure or auditing, scope or procedure.

     There were no "reportable events" (as such term is defined in Item 304 of
Regulation S-K) that occurred within the Company's two most recent fiscal years
nor any subsequent interim period preceding the replacement of Roy A. Cohen,
C.P.A.

     During the Company's two most recent fiscal years and any subsequent
interim period prior to the engagement of Singer Lewak Greenbaum & Goldstein
LLP, neither the Company nor anyone on the Company's behalf consulted with
Singer, Lewak Greenbaum & Goldstein LLP, regarding either (i) the application of
accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered on the Company's financial
statements or (ii) any matter that was either the subject of a "disagreement" or
a "reportable event."

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS.

         (a)      Financial Statements - None.
         (b)      Exhibits - None.




                                       2

<PAGE>


                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                        MEDITECH PHARMACEUTICALS, INC.


September 6, 2000                       By: /s/ Gerald N. Kern
                                            ------------------------------------
                                                Gerald N. Kern,
                                                Chief Executive Officer




                                       3
[{"type": "8-K", "sequence": "1", "filename": "0001.txt", "description": "FORM 8-K", "secsgml_size_bytes": 4121}]
{"company-data": {"conformed-name": "MEDITECH PHARMACEUTICALS INC", "cik": "0000717588", "assigned-sic": "2834", "irs-number": "953819300", "state-of-incorporation": "NV", "fiscal-year-end": "0531"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12561", "film-number": "718818"}, "business-address": {"street1": "10105 E VIA LINDA #103", "street2": "PMB 382", "city": "SCOTTSDALE", "state": "AZ", "zip": "85258", "phone": "4806142874"}, "mail-address": {"street1": "10105 E VIA LINDA", "street2": "103 382", "city": "SCOTTSDALE", "state": "AZ", "zip": "85258"}}
SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                Current Report Pursuant to Section 13 or 15(d) of
                           The Securities Act of 1934

Date of Report (Date of earliest event reported):             September 6, 2000

                         MEDITECH PHARMACEUTICALS, INC.
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)

      NEVADA                         0-12561                    95-3819300
  (State or other                  (Commission               (I.R.S. Employer
   jurisdiction                   File Number)              Identification No.)
 of incorporation)

                             10105 E. Via Linda, #103
                                     PMB 382
                                Phoenix, Arizona                        85258
                       --------------------------------------          --------
                      (Address of principal executive offices)        (Zip Code)

Registrant's telephone number, including area code:  (480) 614-2874
ITEM 5.  OTHER EVENTS.

     On September 6, 2000, the Company's Board of Directors approved the
engagement of Singer Lewak Greenbaum & Goldstein LLP, as the Company's
independent certified public accountants, to audit the Company's financial
statements for the fiscal year ending May 31, 2001. Singer Lewak Greenbaum &
Goldstein, LLP, was also engaged to audit the Company's financial statements for
the fiscal years ended May 31, 2000, and each of the two years in the period
then ended, for inclusion in a Form SB-2 registration statement which will be
filed by the Company. The engagement of Singer Lewak Greenbaum & Goldstein LLP,
follows the replacement of Roy A. Cohen, C.P.A., who had been engaged to audit
the Company's financial statements for the fiscal years ended May 31, 1985
through 2000. The audit reports provided by Roy A. Cohen, C.P.A. for the prior
two fiscal years did not contain an adverse opinion or disclaimer of opinion;
however, the audit reports for such periods did contain a going concern
qualification.

     Management of the Company knows of no past or present disagreements between
the Company and Roy A. Cohen, C.P.A., on any matter of accounting principles or
practices, financial statement disclosure or auditing, scope or procedure.

     There were no "reportable events" (as such term is defined in Item 304 of
Regulation S-K) that occurred within the Company's two most recent fiscal years
nor any subsequent interim period preceding the replacement of Roy A. Cohen,
C.P.A.

     During the Company's two most recent fiscal years and any subsequent
interim period prior to the engagement of Singer Lewak Greenbaum & Goldstein
LLP, neither the Company nor anyone on the Company's behalf consulted with
Singer, Lewak Greenbaum & Goldstein LLP, regarding either (i) the application of
accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered on the Company's financial
statements or (ii) any matter that was either the subject of a "disagreement" or
a "reportable event."

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS.

         (a)      Financial Statements - None.
         (b)      Exhibits - None.

                                       2
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        MEDITECH PHARMACEUTICALS, INC.

September 6, 2000                       By: /s/ Gerald N. Kern
                                            ------------------------------------
                                                Gerald N. Kern,
                                                Chief Executive Officer

                                       3